Literature DB >> 728386

Synthesis of peptides of arginine chloromethyl ketone. Selective inactivation of human plasma kallikrein.

C Kettner, E Shaw.   

Abstract

Synthetic procedures have been developed for the preparation of peptides of arginine chloromethyl ketone and applied in the preparation of affinity labels which correspond to the -Pro-Phe-Arg- C terminus of bradykinin, a physiological cleavage site of kallikrein in kininogen. Two such reagents, Ala-Phe-ArgCH2C1 and Pro-Phe-ArgCH2C1, proved to be highly effective as well as selective affinity labels for human plasma kallikrein. For example, Pro-Phe-ArgCH2C1 inactivates plasma kallikrein 50% in 24 min at a concentration of 2 x 10(-8)M, while other trypsin-like proteases are less susceptible in inactivation than kallikrein, differing by a factor of 48 for plasmin and factors of 10(2)-10(5) for factor Xa, thrombin, and urokinase. The affinity of human plasma kallikrein for Ala-Phe-ArgCH2C1 (Ki = 0.078 micron) is about 60 times that for Ala-Phe-LysCH2C1(Ki = 4.9 micron), whereas human plasmin exhibits about the same affinity for the former affinity label (Ki = 1.3 micron) as for the latter (Ki = 0.83 micron). The rate constants for the irreversible step of the affinity labeling reaction, k2, are similar for affinity labels tested with the individual proteases: 0.35 min-1 for plasma kallikrein and 0.18 min-1 for plasmin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 728386     DOI: 10.1021/bi00615a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  17 in total

1.  Translocation of the Csk homologous kinase (Chk/Hyl) controls activity of CD36-anchored Lyn tyrosine kinase in thrombin-stimulated platelets.

Authors:  A Hirao; I Hamaguchi; T Suda; N Yamaguchi
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

2.  Competitive inhibition of human skin collagenase by N-benzyloxycarbonyl-L-prolyl-L-alanyl-3-amino-2-oxopropyl-L-leucyl-L- alanylglycine ethyl ester.

Authors:  D A Wallace; S R Bates; B Walker; G Kay; J White; D J Guthrie; N L Blumson; D T Elmore
Journal:  Biochem J       Date:  1986-11-01       Impact factor: 3.857

3.  Activation of the contact system at the surface of Fusobacterium necrophorum represents a possible virulence mechanism in Lemièrre's syndrome.

Authors:  Karin Holm; Inga-Maria Frick; Lars Björck; Magnus Rasmussen
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

4.  Isolation and characterization of a trypsin-like serine proteinase from the membranes of Walker 256 carcino-sarcoma cells.

Authors:  V J LaBombardi; E Shaw; J F DiStefano; G Beck; F Brown; S Zucker
Journal:  Biochem J       Date:  1983-06-01       Impact factor: 3.857

5.  Evaluation of inhibitor constants and alkylation rates for a series of thrombin affinity labels.

Authors:  B Walker; P Wikstrom; E Shaw
Journal:  Biochem J       Date:  1985-09-15       Impact factor: 3.857

6.  Kallikrein-like activity of crotalase, a snake venom enzyme that clots fibrinogen.

Authors:  F S Markland; C Kettner; S Schiffman; E Shaw; S S Bajwa; K N Reddy; H Kirakossian; G B Patkos; I Theodor; H Pirkle
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Human plasma kallikrein. A rapid purification method with high yield.

Authors:  H Nagase; A J Barrett
Journal:  Biochem J       Date:  1981-01-01       Impact factor: 3.857

8.  Peptide thioesters and 4-nitroanilides as substrates for porcine pancreatic kallikrein.

Authors:  J C Powers; B J McRae; T Tanaka; K Cho; R R Cook
Journal:  Biochem J       Date:  1984-06-01       Impact factor: 3.857

9.  Protease-activated "prodrugs" for cancer chemotherapy.

Authors:  P L Carl; P K Chakravarty; J A Katzenellenbogen; M J Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

10.  Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis.

Authors:  Yves Decrem; Géraldine Rath; Virginie Blasioli; Philippe Cauchie; Séverine Robert; Jérôme Beaufays; Jean-Marie Frère; Olivier Feron; Jean-Michel Dogné; Chantal Dessy; Luc Vanhamme; Edmond Godfroid
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.